Insulin is a small protein which would be destroyed by the stomach’s acidic juices if taken orally. It has been used by an injection under the skin since its introduction in 1922. However, it could possibly be taken any other way which bypasses the digestive system, such as by inhalation...
Semglee(insulin glargine-yfgn) - July 28, 2021 Riabni(rituximab-arrx) - December 17, 2020 Hulio(adalimumab-fkjp) - July 6, 2020 Nyvepria(pegfilgrastim-apgf) - June 10, 2020 Avsola(infliximab-axxq) - December 6, 2019 Abrilada(adalimumab-afzb) - November 15, 2019 ...
GIP is secreted by K-cells in jejunum in response to food intake and its physiological role includes stimulation of insulin secretion, increased glucagon secretion, increased lipogenesis and enhancement of lipid buffering capacity (Fig.1) [34]. In the context of T2D, the ability of GIP to stimu...
A biosimilar is not considered a “generic” in the same way that a traditional, small molecule drug (for example: ibuprofen or acetaminophen) is determined to be a generic. Biosimilars are "similar" because they are biologics that do not have to be exact copies of the active ingredient, as...
Insulin glargine is the first insulin analogue to provide, in a majority of patients, a continuous level of insulin without a pronounced peak after a single daily injection, closely mimicking the normal pancreatic release of basal insulin in healthy individuals. Clinical experience is providing many ...
India’s Biocon has launched insulin glargine in more than 20 emerging markets, including Malaysia (through CCM Pharmaceuticals), Mexico (PiSA Farmacéutica), and Algeria (Abdi Ibrahim). Similarly, Dr. Reddy’s has launched its rituximab biosimilar Reditux in Chile, Ecuador, Peru, Russia, ...
The year 2021 marks the 100th anniversary of the discovery of insulin by Frederick Banting and John Macleod;3,4 since then, insulin therapy has evolved considerably (Figure 14-6). The first BI analog, insulin glargine 100 units(U)/mL7 (Gla-100), introduced in 2000, was ...
The following day, the EMDAC recommended in a 12-2 vote to approve Sanofi-Aventis' new fixed-dose combination of lixisenatide and insulin glargine (Lantus), also indicated as an add-on to lifestyle management for type 2 diabetes. Two new combo injectables for 2DM may be on horizon Health...
Patients were randomized in a 2:1 ratio to receive either detemir or glargine for 52 weeks. The basal insulin was initially adm... S Heller,C Koenen,B Bode - 《Clinical Therapeutics》 被引量: 142发表: 2009年 Stem and progenitor cell-based therapy in ischaemic heart disease: promise, ...
et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 377, 924–931 (2011). Article CAS Google Scholar Cohen, J.A...